Solvonis Therapeutics hails "major breakthrough" from SVN-001 data
(Alliance News) - Solvonis Therapeutics PLC on Tuesday celebrated new analyses from the phase 2 KARE trial of its severe alcohol use disorder treatment SVN-001, which it said showed "a genuine structural difference" compared to other drugs. Read More